Cargando…
The factor VIII treatment history of non‐severe hemophilia A
BACKGROUND: In patients with non‐severe hemophilia A, we lack detailed knowledge on the timing of treatment with factor VIII (FVIII) concentrates. This knowledge could provide information about the expected treatment timing in patients with severe hemophilia A treated with non‐replacement therapies....
Autores principales: | Abdi, Amal, Kloosterman, Fabienne R., Eckhardt, Corien L., Male, Christoph, Castaman, Giancarlo, Fischer, Kathelijn, Beckers, Erik A. M., Kruip, Marieke J. H. A., Peerlinck, Kathelijne, Mancuso, Maria Elisa, Santoro, Cristina, Hay, Charles R., Platokouki, Helen, van der Bom, Johanna G., Gouw, Samantha C., Fijnvandraat, Karin, Hart, Dan P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756346/ https://www.ncbi.nlm.nih.gov/pubmed/32877570 http://dx.doi.org/10.1111/jth.15076 |
Ejemplares similares
-
Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study
por: Abdi, Amal, et al.
Publicado: (2021) -
Joint status of patients with nonsevere hemophilia A
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022) -
Hemophilia management: Huge impact of a tiny difference
por: Kloosterman, Fabienne, et al.
Publicado: (2020) -
Validation of PROMIS Profile‐29 in adults with hemophilia in the Netherlands
por: van Balen, Erna C., et al.
Publicado: (2021) -
Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)